[A special flicker fusion frequency method for detection of the effects of gerontopharmaceuticals exemplified by the L-eburnamonine study].
A clear difference between active drug and placebo is not always found when using the ascending and descending thresholds of the critical flicker fusion test (CFF). We selected a test requiring attention and concentration and performed again the CFF after this 6-minute concentration-test (reactive CFF). This reactive CFF was then used in a double-blind study in 30 ambulant patients with cerebro-vascular arteriosclerosis treated for 8 weeks with 80 mg/day cervoxan or placebo. After the treatment period the reaction of the CFF after the 6-minute concentration-test demonstrated a significantly more frequent improvement of the vigilance in the Cervoxan group compared to the placebo group.
D000368:Aged; D003704:Dementia / Q000188:drug therapy*; D005425:Flicker Fusion / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D012684:Sensory Thresholds; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C016422:eburnamonine
Eine spezielle Flimmerverschmelzungs-frequenz-Methode zur Erfassung von Gerontopharmaka-Wirkungen am Beispiel einer L-Eburnamonine-Studie.